UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/774,721	02/09/2004	Ralf Jockers	FRAV2003/0005USNP	9535
⁵⁴⁸⁷ ANDREA Q. R	7590 06/03/200 YAN	EXAMINER		
SANOFI-AVE	NTIS U.S. LLC	WOLLENBERGER, LOUIS V		
1041 ROUTE 202-206 MAIL CODE: D303A			ART UNIT	PAPER NUMBER
BRIDGEWATI	ER, NJ 08807	1635		
			NOTIFICATION DATE	DELIVERY MODE
			06/03/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com andrea.ryan@sanofi-aventis.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/774,721	JOCKERS ET AL.	
Examiner	Art Unit	
Louis Wollenberger	1635	

The MAILING DATE of this communication appears on the cover sheet with the corre	spondence address
THE REPLY FILED <u>20 May 2009</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOW	VANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appea application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or of application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 3 for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within periods:	other evidence, which places the 37 CFR 41.31; or (3) a Request
a) $\boxed{\underline{}}$ The period for reply expires $\underline{5}$ months from the mailing date of the final rejection.	
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date	
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRS MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) have been filed is the date for purposes of determining the period of extension and the corresponding amount of the under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	fee. The appropriate extension fee set in the final Office action; or (2) as
2. 🔯 The Notice of Appeal was filed on <u>20 May 2009</u> . A brief in compliance with 37 CFR 41.37 must be	e filed within two months of the
date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in	to avoid dismissal of the appeal.
<u>AMENDMENTS</u>	
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will n (a) They raise new issues that would require further consideration and/or search (see NOTE be (b) They raise the issue of new matter (see NOTE below);	
(c) 🖾 They are not deemed to place the application in better form for appeal by materially reducing	g or simplifying the issues for
appeal; and/or (d) ☐ They present additional claims without canceling a corresponding number of finally rejected	claims
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.116 and 41.33(a)).	ciairis.
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliance	unt Amondmont (PTOL 324)
 4. ☐ Applicant's reply has overcome the following rejection(s): 	int Amendment (F10L-324).
 Applicant's reply has overcome the following rejection(s) Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely 	, filed emendment concelling the
non-allowable claim(s).	_
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered will be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:	entered and an explanation of
Claim(s) allowed: Claim(s) objected to:	
Claim(s) objected to: Claim(s) rejected: <u>12,14,15,17 and 47-54</u> .	
Claim(s) withdrawn from consideration:	
AFFIDAVIT OR OTHER EVIDENCE	
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of because applicant failed to provide a showing of good and sufficient reasons why the affidavit or of was not earlier presented. See 37 CFR 1.116(e).	of Appeal will <u>not</u> be entered other evidence is necessary and
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37	l/or appellant fails to provide a
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is REQUEST FOR RECONSIDERATION/OTHER	s below or attached.
11. The request for reconsideration has been considered but does NOT place the application in cond	dition for allowance because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s)13. Other:	
/Louis Wollenberger/	
Primary Examiner, Art Unit 1	635
May 28, 2009	

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 3. NOTE: The proposed amendments to the claims substitute the limitation "iRNA" with the limitation "antisense oligonucleotide," which has not been previously searched or considered for patentability in the context of the claimed nucleic acid sequence, vector, cell, and compositions.

Continuation of 11. does NOT place the application in condition for allowance because the arguments are directed to proposed amendments that have not been entered.